新型四环素类似物奥马环素和依拉环素对.耐药临床分离株的活性
Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of .
机构信息
Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
出版信息
Antimicrob Agents Chemother. 2019 May 24;63(6). doi: 10.1128/AAC.00470-19. Print 2019 Jun.
Abstract
Tigecycline is used in multidrug regimens for salvage therapy of infections but is often poorly tolerated and has no oral formulation. Here, we report similar activity of two newly approved tetracycline analogs, omadacycline and eravacycline, against 28 drug-resistant clinical isolates of complex. Since omadacycline and eravacycline appear to be better tolerated than tigecycline and since omadacycline is also formulated for oral dosing, these tetracycline analogs may represent new treatment options for infections.
摘要
替加环素用于多种药物方案的补救治疗感染，但往往耐受性差，且无口服制剂。在这里，我们报告了两种新批准的四环素类似物，奥马环素和依拉环素，对 28 种耐药的复杂临床分离株的类似活性。由于奥马环素和依拉环素似乎比替加环素更耐受，并且奥马环素也可制成口服剂型，这些四环素类似物可能代表了 感染的新治疗选择。
相似文献
1
Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of .
Antimicrob Agents Chemother. 2019 May 24;63(6). doi: 10.1128/AAC.00470-19. Print 2019 Jun.
2
Antimicrobial Activities of Tigecycline, Eravacycline, Omadacycline, and Sarecycline against Rapidly Growing Mycobacteria.
Microbiol Spectr. 2023 Feb 14;11(1):e0323822. doi: 10.1128/spectrum.03238-22. Epub 2022 Dec 8.
3
Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus.
J Antimicrob Chemother. 2019 Oct 1;74(10):2930-2933. doi: 10.1093/jac/dkz267.
4
Susceptibility Testing of Eravacycline against Nontuberculous Mycobacteria.
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0068922. doi: 10.1128/aac.00689-22. Epub 2022 Aug 9.
5
Omadacycline, Eravacycline, and Tigecycline Express Anti-Mycobacterium abscessus Activity .
Microbiol Spectr. 2023 Jun 15;11(3):e0071823. doi: 10.1128/spectrum.00718-23. Epub 2023 May 4.
6
Susceptibility Testing of Omadacycline against Nontuberculous Mycobacteria.
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.01947-20.
7
High Levels of Intrinsic Tetracycline Resistance in Mycobacterium abscessus Are Conferred by a Tetracycline-Modifying Monooxygenase.
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.00119-18. Print 2018 Jun.
8
Activities of Omadacycline against Rapidly Growing Mycobacteria.
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.02522-18. Print 2019 May.
9
Efficacies of omadacycline + amikacin + imipenem and an all-oral regimen omadacycline + clofazimine + linezolid in a mouse model of lung disease.
mSphere. 2024 Jul 30;9(7):e0038124. doi: 10.1128/msphere.00381-24. Epub 2024 Jul 9.
10
Rifabutin Acts in Synergy and Is Bactericidal with Frontline Mycobacterium abscessus Antibiotics Clarithromycin and Tigecycline, Suggesting a Potent Treatment Combination.
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00283-18. Print 2018 Aug.
引用本文的文献
1
In Vitro Susceptibility to Imipenem/Relebactam and Comparators in a Multicentre Collection of Complex Isolates.
Antibiotics (Basel). 2025 Jul 5;14(7):682. doi: 10.3390/antibiotics14070682.
2
Heterogeneity among complex species isolated from pulmonary infection in Taiwan.
Microbiol Spectr. 2025 Jul 7:e0030925. doi: 10.1128/spectrum.00309-25.
3
Targeting Autophagy as a Strategy for Developing New Host-Directed Therapeutics Against Nontuberculous Mycobacteria.
Pathogens. 2025 May 13;14(5):472. doi: 10.3390/pathogens14050472.
4
Development of tetracycline analogues with increased aqueous stability for the treatment of mycobacterial infections.
Tuberculosis (Edinb). 2025 Jan;150:102592. doi: 10.1016/j.tube.2024.102592. Epub 2024 Dec 13.
5
Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis.
Clin Pharmacokinet. 2024 Dec;63(12):1701-1709. doi: 10.1007/s40262-024-01440-w. Epub 2024 Nov 24.
6
Characterization of Exosomes Released from Mycobacterium abscessus-Infected Macrophages.
Proteomics. 2025 Feb;25(3):e202400181. doi: 10.1002/pmic.202400181. Epub 2024 Sep 16.
7
Third-Generation Tetracyclines: Current Knowledge and Therapeutic Potential.
Biomolecules. 2024 Jun 30;14(7):783. doi: 10.3390/biom14070783.
8
Efficacies of omadacycline + amikacin + imipenem and an all-oral regimen omadacycline + clofazimine + linezolid in a mouse model of lung disease.
mSphere. 2024 Jul 30;9(7):e0038124. doi: 10.1128/msphere.00381-24. Epub 2024 Jul 9.
9
Omadacycline powder for research procured from unauthorized commercial vendors may be impure and/or unstable.
Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0063824. doi: 10.1128/aac.00638-24. Epub 2024 Jun 18.
10
Exploring antibiotic resistance mechanisms in for enhanced therapeutic approaches.
Front Microbiol. 2024 Feb 6;15:1331508. doi: 10.3389/fmicb.2024.1331508. eCollection 2024.
本文引用的文献
1
Activities of Omadacycline against Rapidly Growing Mycobacteria.
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.02522-18. Print 2019 May.
2
Omadacycline for Community-Acquired Bacterial Pneumonia.
N Engl J Med. 2019 Feb 7;380(6):517-527. doi: 10.1056/NEJMoa1800201.
3
Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.
N Engl J Med. 2019 Feb 7;380(6):528-538. doi: 10.1056/NEJMoa1800170.
4
Mycobacterium abscessus and Antibiotic Resistance: Same As It Ever Was.
Clin Infect Dis. 2019 Oct 30;69(10):1687-1689. doi: 10.1093/cid/ciz071.
5
Activity of the New β-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β-Lactams against Mycobacterium abscessus Complex Clinical Isolates.
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02623-18. Print 2019 Mar.
6
IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections.
Clin Infect Dis. 2019 Aug 30;69(6):921-929. doi: 10.1093/cid/ciy1029.
7
Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline.
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.01174-18. Print 2018 Nov.
8
Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects.
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.01135-17. Print 2017 Sep.
9
Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus.
Future Microbiol. 2017 May;12(6):473-480. doi: 10.2217/fmb-2016-0234. Epub 2017 Feb 16.
10
Epidemiology of Nontuberculous Mycobacterial Lung Disease and Tuberculosis, Hawaii, USA.
Emerg Infect Dis. 2017 Mar;23(3):439-447. doi: 10.3201/eid2303.161827.
Zotero 插件